Therapeutics & Pipeline

Dupilumab linked to height-percentile gains in pediatric AD

<![CDATA[Corticosteroid Exposure and Dupilumab's Impact on Pediatric Growth]]>
travisdmchenry / pixabay

A 2026 post hoc analysis of children with severe atopic dermatitis found that dupilumab was associated with 3.1 times the odds of gaining at least five height-percentile points by week 16 versus placebo, after adjustment for cumulative topical corticosteroid dose, among children whose baseline height was below the 40th percentile.

The unadjusted odds ratio was 2.5. Adjustment for cumulative topical corticosteroid dose raised the estimate to 3.1, while adjustment for topical-corticosteroid-free days yielded 2.9. The signal therefore remained after the measured steroid-exposure variables were taken into account.

Yet the analysis remains exploratory. A post hoc comparison cannot establish that dupilumab directly improves linear growth, especially when disease control, treatment exposure and the underlying inflammatory burden may all change together.

Lisa Swanson, MD, examined the issue in the second installment of Dermatology Times' Expert Perspectives series, "Beyond the Skin: Sleep, Steroids, and Growth in Children With Atopic Dermatitis." Her discussion integrates clinical trials and observational studies addressing height percentiles, corticosteroid burden and bone alkaline phosphatase (BALP), a biomarker associated with bone formation. It also examines what dupilumab (Dupixent) data mean for skeletal development.

How should clinicians interpret the growth signal?

Topical corticosteroids remain a cornerstone of pediatric AD management because they reduce inflammation, relieve pruritus and control flares. Appropriately prescribed preparations are generally considered safe, but systemic absorption becomes more likely with high-potency products, extensive application, prolonged use or treatment across a compromised skin barrier. Excessive exposure can raise concern for hypothalamic-pituitary-adrenal axis suppression and other systemic effects.

The competing concern is undertreatment. Persistent inflammation, disrupted sleep and substantial disease burden may also affect growth, so a child's observed trajectory may reflect steroid exposure, AD itself or both. That distinction matters when counseling families and comparing treatment groups.

What do longer-term findings show?

In the dupilumab open-label extension, children originally assigned to placebo for 16 weeks then received dupilumab. Their changes in height percentiles and BALP resembled those in children who received dupilumab continuously, offering a longer view of growth-related measures after treatment began.

Among children with baseline height below the 40th percentile, 40.4% of the placebo-to-dupilumab group gained at least five height percentiles between weeks 16 and 52, compared with 50.7% of continuous-dupilumab recipients. The open-label design and exploratory analyses cannot determine the optimal timing of systemic treatment for growth outcomes.

The extension nevertheless raises a clinically reasonable question: whether earlier, sustained control of severe AD could influence developmental measures in children already tracking below the 40th percentile. The data support asking the question; they do not answer it.

Can BALP establish better bone health?

BALP is produced by osteoblasts and reflects aspects of bone formation. In children, however, levels vary naturally with age and developmental stage, which complicates interpretation. A change in BALP does not directly demonstrate greater bone mineral density, stronger bones or improved long-term skeletal outcomes.

One proposed pathway runs through symptom control: reducing itch and improving sleep might support favorable growth-related changes. The referenced post hoc analysis did not directly measure sleep, leaving the mechanism untested. Researchers therefore have evidence to continue investigating, not a basis for claiming that dupilumab improves bone health.

What does the observational evidence add?

A 2025 TriNetX retrospective cohort analysis by Chen and colleagues found greater risk of height below the fifth percentile in children with AD than in matched controls (relative risk, 1.15; 95% CI, 1.12-1.18). The association does not show that AD causes impaired growth, because the retrospective design cannot resolve causation.

An Italian multicenter retrospective study followed 47 children aged 6 months to 5 years receiving dupilumab and found no negative effect on growth over 52 weeks. Reassuring as that sounds, the sample was small and the design observational, limiting generalizability.

What does this change for treatment decisions?

For children with moderate to severe AD, clinicians should consider corticosteroid exposure, persistent inflammation, sleep disturbance and baseline growth pattern when assessing disease burden. None of the current findings supports prescribing dupilumab specifically to improve height or bone density.

Treatment choices should continue to follow established indications, disease severity, age, prior treatment response and individual clinical circumstances. More prospective studies with longer follow-up are needed to determine whether sustained disease control itself influences growth and skeletal development.

Source: dermatologytimes.com

Share this article:

Sophie Lindqvist

Show full bio

Market editor covering people, launches and day-to-day practice in Clinical dermatology, inflammatory skin disease and biologics at Derm Field.

More from Sophie Lindqvist →

Related articles

« Previous article